Literature DB >> 6774993

Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone- and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects.

A Barbarino, L De Marinis.   

Abstract

Although it has been well established that Ca2+ plays an essential role in the release of several hormones, very little is known of the interactions between Ca2+ and secretagogues in the process of pituitary hormone release. One possible way of studying the mechanism of action of hypothalamic releasing hormones is to study how organic calcium antagonists affect their action. Consequently, we infused the commonly used calcium antagonist, verapamil, into 20 normal subjects (10 men and 10 women; aged 19-37 yr) and studied its effects on both basal pituitary hormone levels and augmented hormonal release induced by gonadotropin-releasing hormone (GnRH) and TRH. Verapamil, infused at a rate of 5 mg/h for 3 h, induced a significant and marked suppression of circulating LH and FSH levels in both men and women. By the end of the infusion, the suppression of release was greater for LH (60%) than for FSH (54%). After the termination of the infusion, plasma gonadotropin concentrations returned progressively to basal levels within 2 h. Verapamil was also capable of blunting the peak incremental gonadotropin response to GnRH. Although the basal TSH concentration was apparently unaffected by verapamil, the incremental TSH response to TRH was significantly inhibited in both men and women. Verapamil infusion did not affect either the basal PRL concentration or the PRL response to TRH. Our data provide evidence that verapamil exerts different effects on the release of pituitary hormones in normal subjects. It inhibits the centrally mediated as well as the peripherally mediated gonadotropin release and blunts the TSH response to TRH. On the contrary, verapamil does not seem to affect basal or TRH-mediated PRl release. The use of organic calcium antagonists in experimental models in vitro as well as in vivo appears to offer a promising tool for further studies on the mechanism of action of secretagogues in the process of hormone release.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6774993     DOI: 10.1210/jcem-51-4-749

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Thyrotropin-releasing hormone stimulation of thyrotropin secretion is suppressed by calcium ion antagonists that block transmembrane influx and intracellular mobilization of calcium ion in human subjects.

Authors:  M Yamada; M Mori; M Yamaguchi; H Akiyama; S Shiono; I Kobayashi; S Kobayashi
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

2.  No effect of verapamil on calcium stimulated calcitonin release.

Authors:  J A Amado; C Gómez; C Pesquera; M A Antón; J Freijanes; J González Macías
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

3.  The effect of nicardipine on pituitary hormone release in normal volunteers.

Authors:  T E Isles; J Baty; R J Dow
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 4.  Thyrotropin releasing hormone. A review of the mechanisms of acute stimulation of pituitary hormone release.

Authors:  M C Gershengorn
Journal:  Mol Cell Biochem       Date:  1982-06-25       Impact factor: 3.396

5.  The effect of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man.

Authors:  J A Millar; K A McLean; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Effect of flunarizine on pituitary secretion by healthy men and in woman with migraine.

Authors:  E Maestri; G C Manzoni; G Marchesi; L Camellini; G Rossi; G Veneri; A Gnudi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Calcium antagonists and endocrine status: lack of effect of oral verapamil on pituitary-testicular and pituitary-thyroid function.

Authors:  C G Semple; J A Thomson; G H Beastall; A R Lorimer
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

8.  Flunarizine increases PRL secretion in normal and in migraineous women.

Authors:  U Bonuccelli; P Piccini; A M Paoletti; A Nuti; A Colzi; G B Melis; A Muratorio
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 9.  Calcium antagonists and exercise performance.

Authors:  W Kindermann
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

10.  Effect of 1,25-dihydroxyvitamin D3 and nifedipine on prolactin release in normal man.

Authors:  D Verbeelen; L Vanhaelst; M Fuss; A C Van Steirteghem
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.